The Blood Cancer Landscape Report
The Report Offers Insight Into:
- The Clinical Trial Landscape: Leukemia & non-Hodgkin lymphoma drive the highest clinical trial activity due to prevalence, complexity, and unmet need
- Drug Development Pipelines & Targets: Cell therapies dominate pipelines, while CD19 is the most investigated target
- Recent FDA Approvals: Approvals span diverse modalities, including a bispecific antibody, menin inhibitor, and CD19 CAR-T therapy
- Targets Attracting Investments: Deal-making remains strong around B-cell targets (CD3, CD20), while emerging bispecifics and trispecifics attract investor interest
You May Also Be Interested In…
What is Beacon?
Beacon is the essential intelligence platform for R&D decision-makers working in pharma and biotech, offering unique technology and drug datasets for complex therapeutics and disease areas.
Our market-defining proprietary ontologies, manual data curation, and accurate and comprehensive life science data, provide our customers with unparalleled visibility of the drug, trial and commercial landscape.
This is why 24 of the top 25 pharmaceutical companies trust Beacon to power their critical pipeline, competitive, and commercial decisions.
We’d welcome the opportunity to show you how Beacon can transform your data strategy. Book your personalized demonstration today!
